| 292 | 1 | 31 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 基于数据挖掘技术分析国家专利数据库自建库以来中药复方干预糖尿病肾脏疾病(Diabetic kidney disease, DKD)的组方用药规律。方法 计算机检索国家知识产权局和中国知网专利数据库中干预DKD的中药复方,建立处方数据库,运用SPSS Statistics25.0、SPSS Modeler18.0、Cytoscape3.8.0和Gephi0.9.2软件进行频数统计、关联规则分析、聚类分析,导出药物拓扑属性值并构建核心药物网络图。结果 中药复方干预DKD中使用频次≥30次的中药有15味,主要以黄芪(132次)、丹参(69次)、大黄(53次)、山茱萸(53次)、山药(51次)为主;药物功效分类以补虚药(785次,39.47%)、活血化瘀药(258次,12.97%)、清热药(254次,12.77%)、利水渗湿药(169次,8.5%)、收涩药(124次,6.23%)为主;四气五味主要涉及温、寒、平和甘、苦、辛;归经以肝、脾、肾为主。关联规则分析显示,常用对药17组、角药13组。由核心药物网络图得到20味核心中药。系统聚类分析得到5组干预DKD的常用基础方。结论 中药复方专利治疗DKD以益气养阴、滋补肾精、清热泻火、活血利水、解毒泄浊、固摄敛精为主,同时结合“虚、实、肾络”等层面辨证用药。
Abstract:Objective Based on data mining technology, to analyze the medication rules of Chinese herbal compound in intervention ofdiabetic kidney disease in national patent database since establishment. Methods The computer searched the patent database of National Intellectual Property Administration and National Knowledge Infrastructure for Chinese herbal compound prescriptions that intervene in diabetic kidney disease, established a prescription database, and used SPSS Statistics25.0, SPSS Modeler18.0, Cytoscape3.8.0 and Gephi0.9.2 to conduct frequency statistics, association rule analysis, cluster analysis, and derive the topological attribute values of drugs and construct the core drug network diagram. Results 15 Chinese herbal medicines were used more than or equal to 30 times, mainly including Radix Astragali(132 times), Radix Salviae Miltiorrhizae(69 times), Radix et Rhizoma Rhei(53 times), Fructus Corni(53 times) and Rhizoma Dioscoreae(51 times).The drug efficacy categories were mainly tonifying drugs(785 times, 39.47%), drugs for promoting blood circulation and removing blood stasis(258 times, 12.97%), heat-clearing drugs(254 times, 12.77%), drugs for diuresis and diffusing dampness(169 times, 8.5%) and astringent drugs(124 times, 6.23%). The 4 nature of drugs and 5 flavors mainly involved warm, cold, calm, and sweet, bitter, and pungent.The main meridians were liver, spleen and kidney. According to the association rule analysis, 17 groups of commonly used double drugs and 13 groups of triple drugs were obtained. From the core drug network diagram obtained 20 core traditional Chinese medicines. Systematic clustering analysis yielded 5 groups of drug combinations. Conclusion The patented Chinese medicine compound formula for the treatment of diabetic kidney disease is based on benefiting qi and nourishing yin, nourishing kidney essence, clearing heat-fire, promoting blood circulation and diuresis, detoxifying and draining turbidity, and consolidating and astringing essence, andat the same time, it is combined with dialectical medication at the levels of “deficiency, excess, and kidney meridians”.
[1] RUIZ-ORTEGA M,RODRIGUES-DIEZ R R,LAVOZ C,et al.Special issue “diabetic nephropathy:diagnosis,prevention and treatment”[J].J Clin Med,2020,9(3):813.
[2] 丁然然,杨明霞.复方中药治疗糖尿病及其并发症的研究进展[J].实用中医内科杂志,2022,36(5):36-39.
[3] 高裕闻,邱昌龙.中医药治疗糖尿病肾病的研究进展[J].中国医药导报,2022,19(12):38-41.
[4] 惠石生,马莹.白藜芦醇对糖尿病大鼠早期肾脏损伤保护作用的Meta分析[J].新疆医科大学学报,2022,45(3):250-258.
[5] 国家药典委员会.中华人民共和国药典[M].北京:中国医药科技出版社,2020:3-403.
[6] 高学敏,钟赣生.中药学[M].4版.北京:中国中医药出版社,2016:54-440.
[7] 余江毅,倪青,刘苏.糖尿病肾病病证结合诊疗指南[J].中医杂志,2022,63(2):190-197.
[8] 杨柳,李爱平,张王宁,等.黄芪及含黄芪经方在治疗肾病方面的药理作用及临床应用研究进展[J].中草药,2018,49(14):3419-3424.
[9] 陈思琦,李佳欣,吴鑫宇,等.熟地黄的药理学研究进展[J].化学工程师,2019,33(11):46-50.
[10] 李佳欣,陈思琦,葛鹏玲.山茱萸药理学研究进展[J].辽宁中医药大学学报,2022,24(4):63-66.
[11] 范晓阳,侯彦婕,贾世艳,等.山药化学成分及皂苷类成分药理作用的研究进展[J].中医药信息,2021,38(9):79-84.
[12] 管陈安,叶华茂,徐光标,等.熟地黄提取物对糖尿病肾病大鼠AKT/GSK-3β信号通路及足细胞上皮间质转化的影响[J].浙江医学,2021,43(4):358-363,457.
[13] 张文杰,赖星海,陈佳薇.山药多糖治疗肥胖糖尿病肾病大鼠的效果观察及对其肾功能和肠道微生态的影响[J].中国微生态学杂志,2021,33(1):37-42.
[14] 吴平亚,冯磊.丹参素对糖尿病肾病大鼠MEK/ERK/Nrf2通路及肾脏纤维化的影响[J].热带医学杂志,2021,21(10):1260-1264,1376.
[15] 宋炎阁.川芎注射液联合贝那普利治疗糖尿病肾病随机平行对照研究[J].实用中医内科杂志,2019,33(4):13-15.
[16] 徐明杰,赵迪,李龙宇,等.水蛭素的药理作用及临床应用研究进展[J].中国现代中药,2021,23(4):747-754.
[17] 张璇,姜睿斌,薛松研,等.生地黄及其配伍防治糖尿病肾病微炎症状态的药效机制分析[J].现代中西医结合杂志,2021,30(35):3975-3977,3982.
[18] 郝洁,梁艳,张瑞,等.大黄素改善糖脂代谢异常、糖尿病周围神经病变及糖尿病肾病的作用机制研究进展[J].中药药理与临床,2020,36(3):265-272.
[19] 黄倩,林佩璜,王梅爱,等.黄连素对糖尿病肾病大鼠晚期糖基化终末产物及其受体信号传导通路的影响[J].中国临床药理学杂志,2020,36(6):632-635.
[20] 吴伟,冯儒庭,韩琳.黄连素治疗糖尿病肾病鼠和人的系统评价[J].河南中医,2021,41(11):1756-1764.
[21] 杜晓妍,吴娇.茯苓的化学成分和药理作用研究进展[J].新乡医学院学报,2021,38(5):496-500.
[22] 张维君,韩东卫,李冀.泽泻的化学成分及药理作用研究进展[J].中医药学报,2021,49(12):98-102.
[23] 仝小林,周强,赵林华,等.糖尿病肾病的中医辨治经验[J].中华中医药杂志,2014,29(1):144-146.
[24] 刘尚建,王翚,王耀献,等.“肾络微型癥瘕”理论初探[J].中国中医基础医学杂志,2009,15(9):649-650.
[25] 韩宜臻,陶嘉茵,王珍,等.王耀献基于“内热致癥”病机从三焦辨治糖尿病肾病[J].中医学报,2021,36(10):2142-2145.
[26] 南赫,黄晓强,王宣权,等.糖尿病肾病“肾络伏风”病机学说及“从风论治”治法的探讨[J].环球中医药,2020,13(4):620-623.
[27] 赵亚,张勉之,樊威伟,等.国医大师张大宁治疗糖尿病肾病用药经验[J].陕西中医,2021,42(6):773-775,788.
[28] 周春梅,肖洋,路波,等.基于国家专利数据库分析中药复方治疗糖尿病肾病的用药规律[J].中国医药导报,2021,18(31):131-134.
基本信息:
中图分类号:R259;R277.5
引用信息:
[1]郑毅成,高雪,郭宇鑫,等.基于数据挖掘分析国家专利数据库中药复方干预糖尿病肾脏疾病的组方用药规律[J].新疆医科大学学报,2023,46(05):689-694.
基金信息:
国家自然科学基金项目(82004275); 中央高校基本科研业务费专项资金项目(2022-JYB-XJSJJ007)
2023-05-15
2023-05-15